Showing results (111-120 of 426) with videos related to

Sort By:
Pageof 43
RMD Open|July 6, 2019
Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experienceChiara Tani, Elena Elefante, Viola Signorini, et al.
Neurogastroenterology and Motility|April 24, 2019
Assessment of swallowing function with oro-pharyngeal-esophageal scintigraphy in patients with idiopathic inflammatory myopathiesSimone Barsotti, Giulia Puccini, Alessandra Tripoli, et al.
Rheumatology International|October 18, 2017
Muscular vasculitis confined to lower limbs: description of two case reports and a review of the literatureAlessandra Tripoli, Simone Barsotti, Luca Emanuele Pollina, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritisGianluca Furneri, Lorenzo G Mantovani, Andrea Belisari, et al.
Frontiers in Medicine|October 3, 2024
Challenges and opportunities in transitional care process in Behçet's syndromeFederica Di Cianni, Maria Vincenza Mastrolia, Edoardo Biancalana, et al.
Rheumatology (Oxford, England)|July 11, 2023
Actigraphic and self-reported characterization of sleep in systemic lupus erythematosus patientsUgo Faraguna, Caterina Porciani, Alessandro Colitta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
Arthritis Research & Therapy|October 15, 2020
Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosusElena Elefante, Chiara Tani, Chiara Stagnaro, et al.
Clinical and Experimental Rheumatology|October 18, 2012
The rationale of pharmacoeconomic analysis in rheumatologic indicationsGiuseppe Turchetti, Luciana Scalone, Ornella Della Casa Alberighi, et al.
The Lancet. Rheumatology|August 29, 2024
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trialsIoannis Parodis, Julius Lindblom, Roger A Levy, et al.
Pageof 43